RG7800 NEW
| Price | $39 | $64 | $88 |
| Package | 2mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: RG7800 | CAS No.: 1449598-06-4 |
| Purity: 99.9% | Supply Ability: 10g |
| Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | RG7800 |
| Description | RG7800 (RO6885247) has the potential for spinal muscular atrophy treatment. RG7800 is an SMN2 splicing modifier. |
| In vitro | RG7800 has been demonstrated to facilitate the inclusion of exon 7 in SMN2 mRNA, thereby producing full-length mRNA in vitro from fibroblasts sourced from a patient with SMA type I. This compound enhances the level of SMN protein through the induction of alternative splicing in SMN2 mRNA. |
| In vivo | RG7800 displays favorable drug metabolism and pharmacokinetic profile in the rat and in cynomolgus monkey with good oral bioavailability. RG7800 dose-dependently corrects SMN2 splicing by including exon 7 to create FL mRNA, showing that RG7800 corrects alternative splicing of the human SMN2 gene in the brain of transgenic SMA model mice, leading to an increase of the SMN protein in the brain. The treatment of RG7800 displays a clear dose-dependent increase in SMN protein levels in the SMA mouse model. Mice treated with RG7800 demonstrate a dose-dependent increase in survival beginning at the low dose (0.3/1 mg/kg). Approximately 80?90% survive beyond PND50/PND60 with profound body weight gain when the study is terminated, in the middle and high dose groups (1/3 and 3/10 mg/kg, respectively) . |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 1.4 mg/mL (3.36 mM), Sonication and heating are recommended. H2O : 1.25 mg/mL (3.00 mM), when pH is adjusted to 3 with HCl. Sonication is recommended. Ethanol : 2.5 mg/mL (6.00 mM), Sonication is recommended. |
| Keywords | RG7800 | RO-6885247 | Inhibitor | RO 6885247 | DNA/RNA Synthesis | inhibit | RG-7800 | RG 7800 |
| Inhibitors Related | Rifampicin | 5-Fluorouracil | Ribavirin | Guanidine hydrochloride | 2,4-D | Resveratrol | Trimethoprim | Azelaic acid | Acyclovir | Thymidine | Temozolomide | Folic acid |
| Related Compound Libraries | Bioactive Compound Library | ReFRAME Related Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | NO PAINS Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Cell Cycle Compound Library | Anti-Cancer Compound Library | Anti-Cancer Drug Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $0.00/50mg |
VIP1Y
|
TargetMol Chemicals Inc.
|
2024-11-19 | |
| $39.00/2mg |
VIP5Y
|
TargetMol Chemicals Inc.
|
2024-11-19 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY